Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.3K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.3K
Directing Effect of Substituents: meta-Directing Groups01:09

Directing Effect of Substituents: meta-Directing Groups

5.8K
Substituents on the benzene ring that direct an incoming electrophile to undergo substitution at the meta position are called meta directors. All meta directors either have a positive charge on the atom directly bonded to the ring or a partial positive charge. These groups function by withdrawing electrons from the ring through inductive and resonance effects. Consider the carbocation intermediates formed upon the addition of an electrophile on nitrobenzene at the...
5.8K
Directing Effect of Substituents: ortho–para-Directing Groups01:14

Directing Effect of Substituents: ortho–para-Directing Groups

8.3K
Ortho–para directors are substituent groups attached to the benzene ring and direct the addition of an electrophile to the positions ortho or para to the substituent. All electron-donating groups are considered ortho–para directors. They donate electrons to the ring and make the ring more electron-rich. The ring is therefore susceptible to the addition of electrophiles. Substituents such as amino, hydroxy, or alkoxy, containing lone pairs on the atom adjacent to the ring, donate...
8.3K
Directional Relays01:25

Directional Relays

587
Directional relays, essential for managing unidirectional fault currents, enhance the safety and efficiency of power systems. On power lines equipped with directional relays, faults downstream (to the right) of the current transformer typically cause the fault current to lag the bus voltage by approximately 90 degrees, known as the forward direction. In contrast, upstream (left-side) faults may result in the fault current leading the bus voltage by nearly 90 degrees, termed the reverse...
587
Directional Terms01:14

Directional Terms

16.1K
Directional terms are essential for describing the relative locations of different body structures. For instance, an anatomist might describe one band of tissue as "inferior to" another, or a physician might describe a tumor as "superficial to" a deeper body structure. These terms often use comparative terms in pairs to trace out the relative locations of one body part to another or descriptions of body tissues like the deeper ones from superficially present with reference to...
16.1K
Direct Motor Pathways01:11

Direct Motor Pathways

4.3K
The direct motor pathways, also known as the pyramidal tracts, are a group of neural pathways that originate in the brain and descend through the spinal cord. They control the voluntary movement of the body. There are two major direct motor pathways: the corticospinal and the corticobulbar tracts.
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Self-Reported Responses to Nutrition Facts Labels Before and After Nutrition Labeling Policy Implementation: A Comparison of Adults in the United States and Mexico.

Current developments in nutrition·2026
Same author

Increased accrual of diverse patient populations in oncology phase I clinical trials at the University of Colorado Cancer Center.

Frontiers in oncology·2025
Same author

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas.

Cancers·2023
Same author

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.

Journal for immunotherapy of cancer·2023
Same author

Intensive behavioral Therapy for weight loss in patients with, or At-Risk of, type 2 Diabetes: Results from the PaTH to health diabetes study.

Preventive medicine reports·2023

Related Experiment Video

Updated: Jan 23, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

Future directions in soft tissue sarcoma treatment.

Francis Hall1, Victor Villalobos1, Breelyn Wilky1

  • 1Department of Internal Medicine, Division of Medical Oncology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado.

Current Problems in Cancer
|June 24, 2019
PubMed
Summary

New targeted therapies and immunotherapies offer improved treatment options for soft tissue sarcomas (STS), addressing genetic variability and reducing toxic side effects despite poor prognoses.

Keywords:
ALK fusionASPSCR1-TFE3 fusionEZH2/INI1IDH mutationImmunotherapyKITMDM2PDGFRαSarcomaSoft tissue sarcomaTargeted therapyβ-catenin/APC/NOTCH

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Related Experiment Videos

Last Updated: Jan 23, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Sarcomas are diverse mesenchymal malignancies with variable clinical behavior.
  • Histologic subtypes alone do not fully capture the heterogeneity of sarcoma.
  • Advances in genetic sequencing reveal molecular variability, enabling targeted therapies.

Purpose of the Study:

  • To review the current diagnostic and therapeutic landscape of soft tissue sarcomas (STS).
  • To explore emerging targeted therapies and immunotherapies for STS.
  • To highlight progress in precision medicine for sarcoma treatment.

Main Methods:

  • Review of current literature on STS diagnostics and treatment.
  • Discussion of genetic alterations and their targeted therapies.
  • Exploration of advancements in sarcoma immunotherapy.

Main Results:

  • Identification of key molecular targets including PDGFRα/KIT, β-Catenin/APC/NOTCH, IDH-1/2, MDM2, EZH2/INI1, ALK, and ASPSCR1-TFE3.
  • Progress in the development and application of immunotherapies for STS.
  • Emerging therapies show promise in managing STS with potentially fewer side effects.

Conclusions:

  • Targeted therapies and immunotherapies represent a significant advancement in STS treatment.
  • These novel approaches offer more precise treatment strategies compared to traditional methods.
  • Despite persistent challenges, these advancements provide hope for improved patient outcomes in STS.